Pritumumab is under clinical development by Nascent Biotech and currently in Phase I for Glioma. According to GlobalData, Phase I drugs for Glioma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pritumumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pritumumab overview
Pritumumab is under development for the treatment of brain cancers including glioblastoma (GBM), anaplastic astrocytoma (AA), non-small lung cancer, anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), low grade gliomas, brain metastases, meningiomas, chordomas, medulloblastoma, craniopharyngiomas, pituitary tumors orleptomeningeal metastases, pancreatic cancer, lung cancer, breast cancer, colon cancer and Coronavirus disease (COVID-2019). The therapeutic candidate is a human IgG1 kappa antibody. It acts by targeting vimentin. It is administered through intravenous route. The therapeutic candidate is developed based on GPEx technology, multiPharm technology and uberkine technology.It was also under development for the treatment of malignant astrocytoma.
Nascent Biotech overview
Nascent Biotech (Nascent) is clinical-stage biopharmaceutical company. The company delivers human monoclonal antibodies and cytokine for the treatment of cancer and a drug discovery platform for identifying new antibodies and antigens for commercialization. It develops Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies such as lung and breast cancer metastases to the brain; and pancreatic cancer. It offers CLNH5 and MultiPharm, a platform technology proprietary, which have additive and synergistic effects on cancer therapy, diabetes, autoimmunity, and transplantation. Nascent is headquartered in San Diego, California, the US.
For a complete picture of Pritumumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
